ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...
Discover a study that found that the combination of durvalumab and tremelimumab with concurrent radiotherapy is a feasible ...
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...
Blue light cystoscopy had a statistically significant reduction in risk of recurrence versus white light cystoscopy in ...
BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...
7don MSN
These strategies are effective at stopping leaksBy Ashley AbramsonBladder leaks can be disruptive—and they’re very common. Up ...
ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...
Findings in patients with interstitial cystitis/bladder pain syndrome can help with diagnosis of interstitial cystitis subtypes ...
Bladder cancer is one of the most commonly diagnosed cancers, yet many patients face delays in diagnosis or struggle to find the right care. Are you navigating a bladder cancer diagnosis or unsure of ...
Millions of adults have bladder problems. Some people have sudden, strong urges to urinate or an uncontrollable flow. Others ...
Updated clinical & translational results: BOND-003 Cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results